This could be the ace in the hole for Johnson & Johnson's COVID-19 vaccine

J&J is behind in the race to develop a COVID-19 vaccine. But there's one thing that could make it a come-from-behind winner.

| More on:

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Six companies are currently evaluating COVID-19 vaccine candidates in late-stage testing. Johnson & Johnson (NYSE: JNJ) isn't one of them.

J&J was among the first to commit resources to a major effort to fight COVID-19. It established a partnership with the US Government early on to develop a novel coronavirus vaccine. It's the biggest healthcare company in the world, with massive resources. And yet Johnson & Johnson lags well behind multiple rivals, both big and small.

Don't discount J&J's prospects, though. The healthcare giant's COVID-19 vaccine candidate could have an ace in the hole that just might make it the biggest winner of all.

One and done

Johnson & Johnson announced the publication of results from a preclinical study of its lead vaccine candidate, Ad26.COV2-S, on July 30. You might not think preclinical results would be a big deal. After all, several of J&J's rivals in the race to develop COVID-19 vaccines have already announced results from early-stage clinical studies in humans.

The company reported that its experimental vaccine induced a robust immune response in nonhuman primates. In particular, vaccination with Ad26.COV2-S resulted in the production of high levels of neutralizing antibodies, which hold the potential to prevent infection by the coronavirus. J&J noted that its vaccine candidate provided "complete or near-complete protection in the lungs from the virus" in the animals in the preclinical study.

All of that was great news. But what really made these preclinical results stand out was that the impressive immune response was obtained with only a single dose of Ad26.COV2-S. Other COVID-19 vaccine candidates that are farther along in clinical testing require two doses.

There are a couple of key reasons why a "one-and-done" vaccine is preferable to vaccines that require multiple doses. First, a single-dose vaccine is cheaper. Second, people would be more likely to receive a single vaccine dose than they would be to get both doses of a vaccine that requires two.

It's still early, though. J&J is evaluating both one- and two-dose regimens of Ad26.COV2-S in its phase 1/2a clinical studies. The company also plans to include both dosing regimens in its planned phase 3 study. There's a possibility that testing could lead J&J to go with the two-dose approach. However, if the single-dose vaccination works as well in humans as it did in nonhuman primates, Johnson & Johnson could easily vault from laggard to leader in the COVID-19 vaccine space.

Playing the long game

Johnson & Johnson arguably remains something of an underdog in the race to develop a COVID-19 vaccine. Even though the company expects to begin a late-stage study of Ad26.COV2-S in September, it's still well behind several other drugmakers. You also might be surprised that J&J has only won major regulatory approval for one vaccine – ever. And that approval came last month, with European approval of the company's Ebola vaccine.

But J&J appears to be playing the long game pretty well with its COVID-19 vaccine development. It spent more time upfront to identify a candidate that could potentially be administered with only one dose. The company also is charging much less for its vaccine than its top rivals are. Last week, J&J landed a deal with the U.S. government to supply 100 million doses of Ad26.COV2-S for around $1 billion. By comparison, Pfizer and BioNTech are supplying 100 million doses to the US for $1.95 billion.

Lower pricing with fewer doses required might not seem like a smart strategy. Couldn't J&J make a lot more money selling a two-dose vaccine regimen at a price more competitive with its rivals? Sure. The healthcare stock might even be up more year to date if it took this approach.

However, a single-dose vaccine would be much more attractive to governments across the world. And J&J is likely to sell it at cost while the pandemic is ongoing. After the pandemic ends, expect the company to raise its price.

Remember Aesop's fable about the tortoise and the hare? It looks like Johnson & Johnson could be the tortoise in the race to develop a COVID-19 vaccine. The tortoise might win the race in the real world – just as it did in the fable.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Should you invest $1,000 in Apiam Animal Health Limited right now?

Before you buy Apiam Animal Health Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Apiam Animal Health Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Keith Speights owns shares of Pfizer. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on International Stock News

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
International Stock News

Should investors be concerned about Berkshire Hathaway's record $348 billion cash position and third consecutive quarter of no stock buybacks?

Here's what the treasure trove of cash and lack of buybacks signal, and if Berkshire is still an excellent value…

Read more »

Woman in business suit holds both hands out with a question mark above each hand.
International Stock News

AMD vs. Nvidia: Which artificial intelligence stock should you buy on the dip?

Which of these two chip stocks is the better option right now?

Read more »

Woman and man calculating a dividend yield.
International Stock News

Greg Abel is taking over for Warren Buffett at Berkshire Hathaway. Here's what you need to know.

It's hard to imagine the company without the investing legend at its helm.

Read more »

Happy family watching Netflix together.
International Stock News

Netflix stock gained 21.4% last month. Here's how.

Is Netflix on track for a long blockbuster run? Check out what's fuelling investor excitement about the media-streaming veteran right…

Read more »

An elderly man finds out he's made a mistake.
International Stock News

Warren Buffett's career in review: His worst investment decisions

Despite the wins, Buffett has also made plenty of errors in his long career.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
International Stock News

Warren Buffett's career in review: His best investment decisions

Buffett's best buys are simply astonishing.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Meta Platforms is ramping up data center and AI investments. Is the growth stock a buy now?

Let's take a look.

Read more »

A head shot of legendary investor Warren Buffett speaking into a microphone at an event.
International Stock News

Berkshire Hathaway stock plunges after Warren Buffett steps down. Is this a golden opportunity to buy?

Investors might be wondering whether they should be buying or selling Berkshire Hathaway stock now.

Read more »